You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Triple-hit lymphoma

Showing 1 - 25 of 7,529
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Double Hit Lymphoma, Triple Hit Lymphoma Trial in Hangzhou (Selinexor+RCHOP)

Recruiting
  • Double Hit Lymphoma
  • Triple Hit Lymphoma
  • Hangzhou, Zhenjiang, China
    Zhejiang Cancer Hospital
Aug 2, 2023

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023

DLBCL, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Tampa, Florida
  • +1 more
Jan 12, 2022

Lymphoma, Relapsed Lymphoma, Refractory Lymphoma Trial in United States (fimepinostat, Rituximab, venetoclax)

Completed
  • Lymphoma
  • +10 more
  • Los Angeles, California
  • +10 more
May 5, 2021

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Tampa (Fludarabine, Cyclophosphamide,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 12, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Beijing, Tianjin (LCAR-AIO cells product)

Recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • LCAR-AIO cells product
  • Beijing, Beijing, China
  • +1 more
Apr 1, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)

Not yet recruiting
  • High-grade B-cell Lymphoma
  • +8 more
  • Sepantronium Bromide
  • Busan, Korea, Republic of
  • +5 more
Feb 27, 2022

Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United

Recruiting
  • Relapsed Chronic Lymphocytic Leukemia
  • +4 more
  • Phoenix, Arizona
  • +7 more
Apr 28, 2022

Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • +13 more
  • (no location specified)
Aug 29, 2023

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma Trial in Nanjing (Chidamide)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Dec 30, 2021

Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma Trial (CTX-8371)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +4 more
  • (no location specified)
Dec 4, 2023

Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer Trial in United States

Recruiting
  • Non Small Cell Lung Cancer
  • +11 more
  • Denver, Colorado
  • +3 more
Jan 10, 2023

Head Neck Cancer, Cervical Cancer, Endometrial Cancer Trial (ILB-2109, Toripalimab)

Not yet recruiting
  • Head and Neck Cancer
  • +9 more
  • (no location specified)
Jul 12, 2023

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

Acute Lymphocytic Leukemia Trial in Beijing, Tianjin (LCAR-AIO Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • LCAR-AIO Cells
  • Beijing, Beijing, China
  • +1 more
May 31, 2022

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Jan 20, 2023

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

Terminated
Has Results
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in Seattle (Allogeneic Hematopoietic

Recruiting
  • Acute Lymphoblastic Leukemia
  • +16 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 1, 2022

Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

Available
  • Large B-cell Lymphoma
  • +4 more
  • Epcoritamab
  • (no location specified)
Feb 16, 2023

ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood Trial in Australia, United States

Recruiting
  • ALL, Childhood
  • +2 more
  • Los Angeles, California
  • +17 more
Aug 11, 2022

Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer Trial in United Kingdom (NX-1607)

Recruiting
  • Ovarian Cancer, Epithelial
  • +14 more
  • Sutton, Surrey, United Kingdom
  • +6 more
Jul 22, 2022